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Abstract 
We speculated whether or not the expression level of telomerase reverse transcriptase (hTERT) 
would be modulated by agents targeting epigenetics in oral cancer cell lines.  Although hTERT is 
known to be targeted by epigenetic changes, it remains unclear how chemoagents targeting 
epigenetics work on hTERT transcription.  In the present study, the epigenetic effects of histone 
deacetylase (HDAC) inhibitor FR901228 on hTERT transcription were analysed by RT-PCR in 
oral cancer cell lines.  The mRNA expression of hTERT was upregulated after exposure to 
FR901228 in hTERT-negative Hep2 cells, even in the hTERT highly expressed SAS and KB cells.  
Moreover, co-treatment of protein synthesis inhibitor cycloheximide (CHX) resulted in the 
induction of hTERT transcription by FR901228.  This suggests that the induction of hTERT by 
FR901228 requires de novo protein synthesis to some extent and is more likely a direct than an 
indirect effect on epigenetic changes such as histone acetylation / deacetylation.  We further 
examined the effect of FR901228 on c-myc protein, which is one of the main hTERT transcription 
activators.  FR901228 repressed c-myc protein only in the absence of CHX, dependent of the 
enhancement of de novo protein synthesis.  Our results indicate that c-myc protein is repressed 
indirectly by FR901228 but may not contribute FR901228-induced hTERT transcription.  The 
present study showed that the HDAC inhibitor FR901228 induced the hTERT gene by a complex 
mechanism that involved other transcription factors except for c-myc, in addition to the inhibition 
of histone deacetylation. 
KEYWORDS:  hTERT;  FR901228;  Oral cancer;  HDAC inhibitor 
 
Introduction 
Telomerase is an enzyme implicated in the de novo synthesis of GGTTAG telomeric DNA onto 
chromosomal ends to stabilize telomeres, concomitant with immortality in cancer cells [3, 26, 16].  
Telomerase is composed of telomerase reverse transcriptase (hTERT) [27], telomerase-associated 
protein (TEP1) [9],  and hnRNP A1 [21].   The de novo transcription of the hTERT gene is 
considered the dominant, rate-limiting step in telomerase activation whereas the expression of 
hTEP1 and hTR is constitutive [1, 9].   The regulation of hTERT expression is complicated, and it 
has been reported that hTERT transcription can be activated by overexpression or activation of 
several transcription activators [8, 17, 20, 24, 33, 36].  Several recent reports have identified c-myc 
binding sites (E-boxes) in the hTERT promoter and found that c-myc positively regulates hTERT 
expression [11, 30].  The hTERT gene is likely to be targeted by epigenetic regulation such as 
histone acetylation or promoter methylation.  Some reports showed that the histone deacetylase 
(HDAC) inhibitor trichostatin A (TSA) could activate hTERT expression in telomerase-negative 
cells [6, 7, 31, 37].  Hou et al. reported that TSA and the protein synthesis inhibitor cycloheximide 
(CHX) induced hTERT mRNA [13], suggesting that this induction does not require de novo 
protein synthesis and is likely a direct result of HDAC inhibition at the hTERT gene.  Although it 
is reasonable to speculate that epigenetic changes such as histone acetylation or promoter 
methylation are common underlying features to hTERT transcriptional regulation, it remains 
unclear how chemoagents targeting epigenetics such as HDAC inhibitors work on hTERT mRNA 
expression.  FR901288, a novel cyclic peptide inhibitor of HDAC, is isolated by the Fujisawa 
Pharmaceutical Co., Ltd. (Osaka, Japan) from a fermantation broth of Chromobacterium 
violaceum, and is currently in phase I of clinical trials.  As FR901228 has a stronger cytotoxic 
activity than TSA, several numbers of genes involved are known to increase or decrease their 
transcriptional levels followed by hyperacetylation of histone [25].   
In the present study, we focus on the HDAC inhibitor FR901228 and evaluate the effects of 
FR901228 on hTERT expression and its transcription activator c-myc in oral cancer cells.   
 
Materials and Methods 
 
Cell lines and culture   
Human oral cancer cell lines (HSC4, HSC3, HSC2, KB, SAS, Hep2and HO-1-u-1) obtained from 
the Cell Resource Center for Biomedical Research Institute of Development, Aging and Cancer, 
Tohoku University, were maintained in Dulbecco’s modified Eagles medium (MDEM) (Nissui 
Pharmaceutical Co. Ltd., Tokyo, Japan) supplemented with 10% fetal bovine serum (FBS) 
(Hyclone Laboratories Inc., UT, USA), 100 units/ml penicillin (Meiji Seika Ltd., Tokyo, Japan) and 
100 µg/ml streptomycin (Meiji Seika Ltd., Tokyo, Japan) in a CO2 incubator (Sanyo Electric Co., 
Ltd., Osaka, Japan) with 95% air plus 5% CO2 at 37℃. 
 
Chemicals 
FR901228 was a gift from Fujisawa Pharmaceutical Company (Osaka, Japan).   FR901288, 
5-Aza-2’-deoxycytidine (5-Aza) (Sigma Chemical Co., St Louis, MO) and CHX (Wako Pure 
Chemical Industries, Ltd., Osaka, Japan) diluted in water were added to MDEM to the final 
concentration indicated in each treatment.  
 
FR901228 treatment   
First, 1 × 106 cells were seeded in 5 ml MDEM in a flask (Nalge Nunc International, cat No. 
152094, Roslilde, Denmark).  Then, 24 h after seeding, the medium was changed for one 
containing FR901228 at final concentration of 0.5 or 1.0 μM and the flask was immersed in a 37℃ 
water bath (Taitec, Co., Ltd., Saitama, Japan).  Cells were also incubated with FR901228 in the 
presence of 200 μg/ml of CHX, a potent protein synthesis inhibitor.  CHX was added to cells 30 
min before the addition of 0.5μM FR901228.  Cells were harvested at the indicated times (4 or 
16hrs) following FR901228 treatment. 
 
5-Aza-2’-deoxycytidine treatment  
Stock solutions of 5-Aza were prepared by dissolving the drug at a concentration of 10 mM in 
distilled water no more than 2 h prior to use in an experiment; final treatment concentrations were 
obtained by diluting the stock solution directly into the tissue culture medium.  Cells were 
incubated with several concentrations of 5-Aza of 4.4 and 8.8 µM for 7 days.  
 
RNA isolation and RT-PCR 
Following incubation of the cells with agents under each experimental condition, extraction of total 
cellular RNA was carried out using Trizol reagent (Invitrogen Corp., Carlsbad, CA) according to 
the manufacturer’s instructions. 1.5µg RNA was reverse-transcribed with Superscript II Reverse 
Transcriptase and oligo dT primers (Invitrogen Corp., Carlsbad, CA). Amplification of cDNAs was 
performed under the following PCR conditions: 7 min at 94℃ for 1 cycle; then 26 cycles at 94℃ 
for 30 s, 59℃ for 30 s, 72℃ for 30 s; and a final elongation step at 72℃ for 10 min. The primers 
used for the amplification were as follows: 
hTERT primer1: sense: 5’- cgg aag agt gtc tgg agc aa-3’, antisense: 5’- gga tga agc gga gtc tgg a 
-3’; hTERT primers1 amplified a 145bp product [18, 27].  hTERT primer2: sense: 5’- act ttg tca 
agg tgg atg tga cgg -3’ (exon6), antisense: 5’- aag aaa tca tcc acc aaa cgc agg -3’ (exon10); hTERT 
primers2 amplified a 493bp product spanning exon6 to exon10 [5, 15, 28].  c-myc: sense: 
5’-aagtcctgcgcctcgcaa-3’, antisense: 5’-gctgtggcctccagcaga-3’.  GAPDH;:sense, 
5’-gaaggtgaaggtcggagtc-3’, antisense: 5’-caaagttgtcatggatgacc-3’.  The amplified GAPDH 
fragment was used as a positive control. The RT-PCR products were separated by electrophoresis 
on a 2% agarose gel, stained with ethidium bromide, and viewed by UV.  
 
Western blotting 
Following incubation of the cells with FR901228 treatment, extraction of total cellular protein was 
carried out using 500µl lysis buffer (1.315mM sucrose, 0.3475mM sodium dodecyl sulfate, 
31.25µl 1M Tris (pH6.8), 0.125mg Bromo Phenol Blue powder, 25µl 2-Mercaptoethanol, diluted 
to 500µl with distilled water).  5µl protein in cell-free extract was loaded per lane and was 
separated by electrophoresis by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS PAGE), and the individual proteins transferred to polyvinylidene difluoride membranes 
(Bio-Rad Laboratories, Hercules, CA) using a semi-dry electrophoretic transfer apparatus 
(LKB-Produkter AB, Bromma, Sweden) at room temperature. The blotted membranes were 
blocked for 1 h in TBS-T (containing 0.1% Tween 20) plus 5% powdered skim milk and then 
probed for 2h with mouse anti-c-myc monoclonal antibody c-myc Ab-5 (Clone 67P05) 
(Neomarkers, Fremont, CA) diluted 1:1000, 2 µg/ml in TBS-T.  The membranes were then 
washed three times in TBS buffer and incubated for 1 h with the appropriate secondary antibody 
horseradish peroxidase-conjugated AffiniPure Goat Anti-Mouse IgG (H+L) (ImmunoResearch 
Laboratories Inc., West Grove, PA) in TBS-T.  Bound antibody was detected using ECL + plus kit 
(Amersham Pharmacia Biotech Inc., Little Chalfont, UK) according to the manufacturer’s 
instructions. To quantify the amount of protein that was loaded per lane, we performed western 
blotting for beta actin as control.  The mouse monoclonal antibody for beta actin, beta actin 
AC-15-ab6276, purchased from Abcam Limited (Cambridge, UK), was diluted 1:5000 in TBS-T 
and utilized in the same manner.   
  
Results 
 
Comparison of hTERT expression among oral cancer cell lines 
The relative levels of hTERT mRNA among seven oral cancer cell lines were determined by 
RT-PCR (Fig. 1).  The great majority of oral cancer cell lines contained detectable amounts of 
hTERT transcript; HSC4 and SAS cells showed especially high levels of mRNA.  Hep2 shows 
no evidence of hTERT message under the specific experimental conditions employed here. 
 
Comparison of hTERT expressions before and after FR901228 or 5-Aza treatment 
The hTERT downregulated cell line Hep2 was incubated with FR901228 at a concentration of 0.5 
or 1.0 μM.  The hTERT-expressed cell lines SAS and KB were also analyzed as a control.  
Substantial amounts of hTERT mRNA were present, as shown in Fig. 2a.  Following incubation 
of the cells with FR901228, very dense bands were detected, suggesting the induction of hTERT 
transcripts in Hep2 cells.  The SAS and KB cells also were upregulated the hTERT expression by 
FR901228 treatment.  
To test whether hTERT gene expression was suppressed by hypermethylation of its promoter 
or not, we exposed 5-Aza, an inhibitor that prevents methylation of newly synthesized DNA, to the 
hTERT downregulated Hep2 cells.  Our results clearly show that the Hep2 cells regained their 
ability to produce high levels of hTERT mRNA following exposure to graded doses of 5-Aza 
(Figure 2a).  
These data suggest that, in both cases, epigenetic-targeted agent-mediated transactivation of 
the hTERT gene might result from localized hyperacetylation of histones or CpG methylation at the 
hTERT promoter. 
 
Effects on hTERT expression of FR901228 treatment combined with CHX 
To determine whether the FR901228-mediated induction of hTERT expression was a direct effect 
or indirect effect, the hTERT downregulated cell line Hep2 and the hTERT-expressed line SAS 
were incubated with FR901228 in the presence of 200 μg/ml of CHX, a potent protein synthesis 
inhibitor, and were then analyzed for hTERT mRNA (Figure 2b).  In FR901228 treatment, all of 
three cells showed inductions of hTERT expression; however, co-treatment of FR901228 with 
CHX resulted even in the enhancement of the hTERT expression in SAS and KB cells.  This 
clearly reflects a direct role for the HDAC inhibitor in the transcriptional activation of the hTERT 
gene to some extent, and implies that de novo protein synthesis is also involved in the hTERT 
regulation. 
 
Comparison of c-myc expressions before and after FR901228 treatment 
Alternatively, we examined whether or not FR901228 has an effect on the hTERT transcription 
activator, c-myc.  Fig. 3 a and b show that FR901228 reduced endogenous expression of c-myc in 
SAS, KB and Hep2 cells.  We further analyzed for c-myc mRNA in those cells incubated with 
FR901228 in the presence of CHX (Figure 3c).  In contrast when cells were exposed to 
FR901228 alone, SAS, KB and Hep2 cells showed less decreasing levels of c-myc mRNA when 
incubated with both FR901228 and CHX.  Interestingly, in Hep2 cells, CHX treatment even 
seems to upregulate baseline expression of c-myc, this seems to depend upon the absence of new 
protein synthesis in the presence of CHX. The rapid reduction of c-myc mRNA in FR901228 
treatment clearly reflects an indirect role for the HDAC inhibitor in the reduction of this gene, but 
both direct and indirect effects are at play.  
 
Discussion  
Among those chemoagents targeting epigenetics, HDAC inhibitors are known to exhibit 
antiproliferative effects on cancer cells through modulating transcription [23, 35], and are 
considered as potential therapeutic agents against malignancies.  Our results showed a clear 
increase in hTERT expression following FR901228 treatment of oral cancer cell lines.  Although 
our findings are the results of in vitro studies and the concentrations of FR901228 in our study are 
higher than those are used in most studies [14, 29], however, we believe that these data may have 
important clinical implications in the potential utility of FR901228 in oral cancer therapy.  Some 
reports showed that the HDAC inhibitor TSA could activate hTERT expression in 
telomerase-negative cells [6, 7, 31, 37].  However, it remains unclear how epigenetics work on 
hTERT mRNA expression.  Horikawa et al. and others [7, 12] found no general correlation 
between the hTERT expression and the hTERT promoter methylation status, either overall or at a 
specific site in cancer cells.  Hou et al. reported that TSA and CHX induced hTERT mRNA [13].  
Wang et al. [34] also reported that TSA-induced hTERT transcription and chromatin alterations 
were not blocked by CHX, suggesting that this induction does not require de novo protein synthesis 
and is likely a direct result of HDAC inhibition at the hTERT promoter.  To characterize whether 
or not the hTERT induction pathway by FR901228 has a direct effect on chromatin, we treated 
cells with FR901228 and the protein synthesis inhibitor CHX.  In SAS or KB cells, co-treatment 
with CHX and FR901228 resulted even in the enhancement of induction of hTERT transcription 
compared with the result obtained by FR901228 treatment alone.  This suggests that the induction 
of hTERT by FR901228 is more likely a direct effect than an indirect effect on epigenetic changes 
such as histone acetylation / deacetylation and involves de novo protein synthesis in part.   
Overexpression of some transcription factors such as c-myc was recently shown to play 
some part in activation of endogeneous hTERT transcription [8, 17, 20, 24, 33, 36].  Next, we 
sought to discover whether or not the effect of FR901228 on hTERT expression is related to a 
mechanism through one of the main hTERT transcription activators, c-myc, whose repression has 
been implicated in several apoptosis pathways [32].  Our results showed that FR901228 treatment 
clearly decreased in c-myc expression in oral cancer cell lines.  HDAC inhibitors, such as TSA 
and sodium butyrate, have been reported to decrease c-myc mRNA expression and to increase p21 
mRNA [35].  Previous studies have shown that butyrate, known as an HDAC inhibitor, reduces 
c-myc mRNA levels [2, 4, 10, 19].  Our results showed that c-myc expression was less reduced in 
the presence of the protein synthesis inhibitor CHX.  This indicates that the c-myc expression is 
transcriptionally regulated by FR901228 through histone acetylation/deacetylation indirectly, 
although the precise mechanism by which HDAC inhibitors abrogate c-myc expression remains to 
be elucidated.  Having demonstrated that FR901228 reduces c-myc expression, the inverse 
expression patterns of hTERT and c-myc led us to hypothesize that c-myc reduction might play 
some part in activating hTERT.  Li et al [22] found a complex consisting of BRCA1, c-myc and 
Nmi that can inhibit hTERT promoter activity in breast cancer cells.  Inconsistent with our 
hypothesis, the combined treatment with FR901228 and CHX resulted in the enhancement of 
hTERT expression independent of c-myc expression.  It is reasonable to speculate that the 
decreased expression of c-Myc protein that was observed in our study is not required for activation 
of the hTERT expression by FR901228.  However, precise mechanism between hTERT and 
c-myc expressions remains to be elucidated.  
Our study suggested that hTERT expression may be regulated epigenetically through histone 
acetylation/DNA methylation to some extent; and other regulatory factors also take part in 
increasing hTERT expression through an HDAC-independent mechanism.  Our study provides 
some new insights into an endogenous mechanism for hTERT induction by HDAC inhibitors.   
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Figure Legends 
 
Figure 1: Comparison of hTERT expression among oral cancer cell lines. 
Extracted RNA was reverse-transcribed to cDNA and the relative levels of hTERT mRNA among 
seven oral cancer cell lines (HSC4, HSC3, HSC2, KB, SAS, Hep2and HO-1-u-1) were determined 
by RT-PCR.  The hTERT primers1 amplified a 145bp product and the hTERT primers2 amplified 
a 493bp product spanning exon6 to exon10.  The two middle bands amplified by primer2 might 
result from partially spliced hTERT transcripts.  The great majority of oral cancer cell lines 
contained detectable amounts of hTERT transcript; HSC4 and SAS cells showed especially high 
levels of mRNA, as indicated by the very dense bands that appear in the relevant lanes.  The gels 
clearly show that Hep2 cells contained no hTERT mRNA under the specific experimental 
conditions employed here.   
 
Figure 2: Epigenetic-targeted agent-mediated transactivation of the hTERT gene. 
a : Comparison of hTERT expressions before and after FR901228 or 
5-Aza-2’-deoxycytidine(5-Aza) treatment.   
Cells of the hTERT-downregulated cell line Hep2 cells were incubated with FR901228 at a 
concentration of 0.5 or 1.0 μM.  The hTERT-high-expressed cell lines, SAS and KB were also 
analyzed as a control.  Substantial amounts of hTERT mRNA were determined by RT-PCR.  
The gels clearly show that the hTERT expression was induced after 4h-16 h of treatment with 
FR901228 in all of three cell lines.  Additionally, the hTERT-downregulated Hep2 cell was 
incubated for 7 days with several concentrations, ranging from 4.4 to 8.8 µM, of 5-Aza, an inhibitor 
that prevents methylation of newly synthesized DNA.  The Hep2 cells regained their ability to 
produce high levels of hTERT mRNA. 
b: Effects on hTERT expression of FR901228 treatment combined with cycloheximide (CHX). 
To determine whether FR901228-mediated induction of hTERT expression was a direct effect or 
not, Hep2, KB and SAS cells were incubated with FR901228 in the presence of 200 μg/ml of 
CHX and were then analyzed for hTERT mRNA by RT-PCR.  SAS, KB and Hep2 cells showed 
slight inductions of hTERT expression; however, co-treatment with CHX resulted even in the 
enhancement of the hTERT expression in comparison with FR901228 alone.   
 
Figure 3: Comparison of c-myc expression before and after FR901228 treatment. 
a: Comparison by RT-PCR of c-myc mRNA before and after FR901228 treatment  
b: Comparison by Western blotting of c-myc protein before and after FR901228 treatment.  
To examine whether or not FR901228 has an effect on the hTERT transcription activator c-myc, 
we analyzed c-myc expression before and after FR901228 treatment in SAS, KB and Hep2 cells.  
FR901228 reduced endogenous expressions of c-myc in both cell lines. 
c: Effects on c-myc expression of FR901228 treatment combined with CHX.   
SAS, KB and Hep2 cells were incubated with FR901228 in the presence of CHX and analyzed for 
c-myc mRNA by RT-PCR.  As when cells were exposed to FR901228 alone, SAS, KB and Hep2 
cells showed less decreasing levels of c-myc mRNA when incubated with both FR901228 and 
CHX.   
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